Kiniksa reports Q1 EPS (25c), consensus (16c)

Reports Q1 revenue $79.858M, consensus $78.46M. “One of the drivers of strong ARCALYST growth is an expanding utilization of ARCALYST as a steroid-sparing therapy for patients suffering from recurrent pericarditis. In addition, with continued frequent prescriber engagement and high physician and patient satisfaction, we now expect 2024 ARCALYST net sales to increase from our previous guidance of between $360 and $380 million to $370 and $390 million,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Additionally, we believe abiprubart has the potential to provide meaningful benefit through convenient subcutaneous dosing, and we plan to initiate a Phase 2b trial in Sjogren’s Disease in the second half of 2024. This continued commercial execution and pipeline advancement is included in our current operating plan, which we expect to remain cash flow positive on an annual basis.”